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Background: Patients with rheumatoid arthritis (RA) are known to be at increased risk of infection, particularly if
they are taking drugs with immunomodulatory effects. There is a need for more information on the risk of influenza
in patients with RA.
Methods: A retrospective cohort study was carried out using data gathered from a large US commercial health
insurance database (Thomson Reuters Medstat MarketScan) from 1 January 2000 to 31 December 2007. Patients
were ≥18 years of age, with at least two RA claims diagnoses. The database was scanned for incidence of seasonal
influenza and its complications on or up to 30 days after an influenza diagnosis in RA patients and matched
controls. Other factors accounted for included medical conditions, use of disease-modifying anti-rheumatic drugs
(DMARDs), use of biological agents, influenza vaccination and high- or low-dose corticosteroids. Incidence rate
ratios (IRRs) were calculated for influenza and its complications in patients with RA.
Results: 46,030 patients with RA and a matching number of controls had a median age of 57 years. The incidence
of influenza was higher in RA patients than in controls (409.33 vs 306.12 cases per 100,000 patient-years), and there
was a 2.75-fold increase in incidence of complications in RA. Presence or absence of DMARDs or biologics had no
significant effect. The adjusted IRR of influenza was statistically significant in patients aged 60–69 years, and
especially among men. A significantly increased rate of influenza complications was observed in women and in
both genders combined (but not in men only) when all age groups were combined. In general, the risk of
influenza complications was similar in RA patients not receiving DMARDs or biologics to that in all RA patients.
Pneumonia rates were significantly higher in women with RA. Rates of stroke/myocardial infarction (MI) were higher
in men, although statistical significance was borderline.
Conclusions: RA is associated with increased incidence of seasonal influenza and its complications. Gender- and
age-specific subgroup data indicate that women generally have a greater rate of complications than men, but that
men primarily have an increased rate of stroke and MI complications. Concomitant DMARD or biological use
appears not to significantly affect the rate of influenza or its complications.Background
Patients with autoimmune rheumatic diseases have a risk
of infection approximately double that of age- and gender-
matched controls [1,2]. The literature suggests that, even
before the use of corticosteroids became widespread,
patients with rheumatoid arthritis (RA) had an increased
susceptibility to infection [3]. This is supported by the* Correspondence: malaria@sunrise.ch
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have RA [4].
Notable diseases in patients with RA include pulmon-
ary infections, particularly pneumonia [5]. The increased
risk of infection in patients with chronic rheumatic or
autoimmune disease is reported to be linked to compro-
mised immunological functioning and to the immuno-
suppressive therapies used to control these disorders
and their organ-specific complications [2]. Over the past
decade, there has been increasing interest in reports oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ies for diseases that include RA [6-8].
A large case-control study based on data from 443 UK
general practices, clarified a number of conditions known
to increase the risk of community-acquired pneumonia
(CAP), and identified seven new independent risk factors
[9]. Conditions increasing risk included RA. Among 17,172
incident cases of all ages diagnosed with CAP between
1995 and 2005, the adjusted odds ratio (OR) for pneumonia
associated with at least one of the already established risk
factors [10] was 2.29 (95% confidence interval [CI]: 2.20,
2.39). After adjustment for known risk factors and confoun-
ders, the OR for risk of pneumonia in 387 patients with RA
was 1.84 (95% CI: 1.62, 2.10).
Although the Mayo Clinic, for example, lists chronic ill-
ness and a weakened immune system as risk factors for in-
fluenza and its complications [11], little is known of the
risk of influenza specifically in patients with RA. We have
carried out a retrospective cohort study based on data gath-
ered over 8 years from a large proprietary US healthcare
database, in order to clarify further the effect of RA on the




This was a retrospective cohort study in patients included
in the Thomson Reuters Medstat MarketScan Database
from 1 January 2000 to 31 December 2007 [12]. Note that
data collection preceded the appearance of the 2009 pan-
demic strain of influenza A (H1N1). Medstat MarketScan
(http://marketscan.thomsonreuters.com/marketscanportal/)
consists of three core commercial health insurance data-
bases (Commercial, Medicare Supplemental and Medicaid)
that cover more than 130 million patients recorded since
1995. The databases link outpatient prescription drug data
with inpatient and outpatient claims files via unique
encrypted patient identifiers, and are used extensively by
health and outcomes researchers for clinical decision sup-
port and healthcare resource allocation planning, and to
study epidemiological patterns. In compliance with the
Health Insurance Portability and Accountability Act
(HIPAA), all patient data used in this study were de-identi-
fied. The project was therefore exempt from Institutional
Review Board approval.
Study population and outcomes
Patients were ≥18 years of age, with at least two RA claims
diagnoses (ICD-9 codes 714.0 or 714.2) [13] on separate
occasions from 1 January 2000 to 31 December 2007. Influ-
enza cases were identified on the basis of an ICD-9 diagno-
sis (487.xx) during the follow-up period. Influenza
complications were defined as: a pneumonia diagnosis
(ICD-9 codes 480.xx–486.xx) on or up to 30 days after aninfluenza diagnosis; diagnosis of stroke or myocardial in-
farction (MI; ICD-9 codes 410.xx, 430, 431, 432.x, 433.xx,
434.xx, 435.xx, 436) on or up to 30 days after an influenza
diagnosis; or diagnosis of a neurological disorder (ICD-9
codes 320.xx–359.xx) on or up to 30 days after an influenza
diagnosis.A single event (ICD-9 diagnosis), regardless of
whether it was based on inpatient or outpatient records,
was considered to be an outcome. The cohort entry date
was that of the first of the two ICD9 diagnoses of RA; a set
period of time between the two diagnoses was not
specified.
Patients not continuously enrolled for 1 year before or
after the date of cohort entry, and those with a diagnosis of
RA or evidence of an RA-related disease in the year preced-
ing the cohort entry, were excluded. A comparator group
of patients who did not have RA was matched 1:1 accord-
ing to age, gender and calendar year, with each case’s cohort
entry date being matched to its control.
Observations
Records of the following conditions or use of medication in
the year prior to cohort entry were taken into account:
 Conditions: cardiovascular disease, chronic lung
disease, diabetes, cancer, HIV/AIDS, organ
transplantation, neurological disorders and depression.




methotrexate, minocycline, sodium aurothiomalate
and sulfasalazine.
 Biologics: abatacept, adalimumab, anakinra,
certolizumab, etanercept, golimumab, infliximab,
rituximab and tocilizumab.
 Influenza vaccination.
Patients were categorized into high or low corticosteroid
use groups based on their average daily dose of corticoster-
oid use assessed in the 6-month period prior to cohort
entry. High or low dose was defined as ≥10mg/day or
<10mg/day the prednisone-equivalent dose, respectively.
Oral glucocorticoid use for drugs other than prednisone
was converted to prednisone-equivalent dosages (see Add-
itional file 1 for conversion table]). The literature indicates
that the use of high-dose corticosteroids can increase the
risk of infection through immunosuppressive effects that
induce cellular immunodeficiency, and that the lowest
dosages possible are preferred [14]. Although data pertain-
ing to low-dose corticosteroid use in patients with RA are
as yet not conclusive [15], there does appear to be a link be-
tween high-dose corticosteroids and infectious complica-
tions (for example in patients with systemic lupus
erythematosus [16]), and corticosteroid use has been
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pandemic influenza A (H1N1) [17].
The observation period was measured in person-years
from cohort entry until termination of enrolment in the
health plan, date of the first diagnosis of influenza or a
complication, or the end of the study period (whichever
came first).
Assessments
Baseline characteristics were assessed according to gen-
der, age and presence of the conditions described earlier
or use of the above medications or vaccines. Differences
in the distributions for patients with an RA diagnosis
versus controls were assessed by χ2 testing. Incidence
rates of influenza and influenza-related complications
were calculated as the number of new cases identified
during the study period per 100,000 person-years for
cases and controls. These rates were then stratified
according to gender and age.
Incidence rate ratios (IRRs) for influenza and its compli-
cations, with 95% CIs, were calculated using Poisson re-
gression (PROC GENMOD, SAS Institute Inc., Cary, NC,
USA), with non-RA patients as reference, and stratification
according to gender and age. Adjusted analyses accounted
for differences in baseline characteristics. The statistical
models adjusted for: ICD-9 claims for cardiovascular dis-
ease, chronic lung disease, transplantation and neurological
disorders; and use of DMARDs, biologics, influenza vaccin-
ation, high-dose corticosteroids, low-dose corticosteroids,
antibiotics and statins.
Analyses were repeated after exclusion of all patients
with a history of DMARD or biological use in the 12
months preceding the date of RA diagnosis. Complica-
tions due to pneumonia or stroke/MI in patients with
RA and controls were also examined, with age stratifica-
tion (i) below 65 years and (ii) 65 years and over.
Results
A total of 46,030 patients with RA and a matching num-
ber of controls were identified from the database
(Table 1). Two-thirds of patients were female, and most
patients were middle-aged or elderly. The largest single
age group was 50–59 years (27.7% of patients), followed
by 60–69 years and then ≥70 years. The median RA
patient/control age was 57 years (Table 1). The most fre-
quent comorbidities were cancer, cardiovascular disease
and diabetes (Table 1). Cardiovascular disease was sig-
nificantly more common in the RA group than in con-
trols (18.10% vs 14.10%; p < 0.0001), but cancer and
diabetes showed similar frequencies between the groups.
Other significantly (p < 0.0001) more frequent conditions
in patients with RA were chronic lung disease (5.37% vs
3.48%), transplantation (2.01% vs 0.91%) and neuro-
logical disorders (7.53% vs 0.4%).The two groups were significantly different (p < 0.0001)
for all medications studied (Table 1). As expected,
DMARDs, biological therapies and corticosteroids were
significantly more frequently used by patients with RA
than the controls; use of low-dose corticosteroids in par-
ticular was markedly more common in the RA group
than the control group. Interestingly, influenza vaccin-
ation was more common in control patients than in those
with RA (10.14% vs 7.60%). Statin and antibiotic con-
sumption was significantly higher in the RA group, al-
though the percentage difference was not as great as in
other medication categories. Notably, of the 46,030
patients with RA, 20,136 (43.75%) had not received
DMARDS, biological therapies or corticosteroids for
their RA from 1 year prior to cohort entry up to the end
of the study. Peak recruitment years were 2004 and 2007,
with 42.51% of patients (39,134 of a total of 92,060 RA
patients and controls) being drawn from the database in
these years. Cohorts did not differ with respect to enrol-
ment by calendar year over the entire period covered.
Overall, the incidence of influenza was higher in per-
sons with RA than in controls (409.33 vs 306.12 cases
per 100,000 patient-years; Table 2 and Figure 1). Inci-
dence was higher in women than in men for both
groups, although the increased incidence of influenza in
RA cases over controls was particularly marked in men
(61% increase vs 24% in women). The lowest incidence
of influenza was in male controls; the highest was in fe-
male RA cases (Table 2). In terms of age, the highest in-
cidence was seen in males aged 30–39 years. The lowest
incidence was in controls aged 60–69 years (Table 2).
The incidence of influenza complications was much
higher in patients with RA than in controls (2.75-fold in-
crease overall; Table 2 and Figure 1). Complications were
most frequent in patients aged ≥70 years: frequencies in
RA patients were more than twice those in controls,
with the highest incidence of all in men with RA aged
≥70 years (Table 2).
Presence or absence of DMARDs or biological therapy
made little or no difference overall to the incidence of
influenza or its complications in either patients with RA
or controls (Table 2 and Figure 1), although there was a
shifting of influenza incidence across age groups when
compared with the overall results. The incidence of in-
fluenza among patients with RA was markedly increased
in the absence of DMARDs or biologics, with clustering
in the younger age groups (18–49 years). The peak inci-
dence of 804.93/100,000 patient-years was in men with
RA aged 30–39 years (Table 2).
Frequencies of pneumonia and stroke/MI complica-
tions were both higher (to a similar extent overall to in-
fluenza complications generally; Figure 1) in patients
with RA. As might be expected, rates were higher in
patients aged 65 years and over for both RA and control
Table 1 Baseline characteristics of patients identified from MarketScan
RA patients (cases) Non-RA patients (controls) p valuea
N % N %
Total no. of patients 46,030 100 46,030 100 –
Age (years)
Mean (SD) 56.61 (14.79) –
Median (IQR) 57 (19) –
18–29 1780 3.87 1780 3.87 1
30–39 4119 8.95 4119 8.95 1
40–49 8064 17.52 8064 17.52 1
50–59 12,735 27.67 12,735 27.67 1
60–69 10,428 22.65 10,428 22.65 1
≥70 8904 19.34 8904 19.34 1
Medical conditions
Cardiovascular disease 8330 18.10 6489 14.10 <0.0001
Chronic lung disease 2470 5.37 1604 3.48 <0.0001
Diabetes 5284 11.48 5475 11.89 0.0501
Cancer 9152 19.88 9362 20.34 0.0842
HIV/AIDS 44 0.10 47 0.10 0.753
Transplant 926 2.01 421 0.91 <0.0001
Renal dysfunction 474 1.03 425 0.92 0.1005
Neurological disorders 3465 7.53 183 0.40 <0.0001
Depression 2555 5.55 2542 5.52 0.8514
Medications at baseline
DMARDs 6413 13.93 642 1.39 <0.0001
Biologics 3276 7.12 104 0.23 <0.0001
Influenza vaccination 3500 7.60 4667 10.14 <0.0001
High-dose corticosteroidsb 10,056 21.85 4990 10.84 <0.0001
Low-dose corticosteroidsb 7903 17.17 1182 2.57 <0.0001
Antibiotics 28,847 62.67 24545 53.32 <0.0001
Statins 7408 16.09 7908 17.18 <0.0001
RA patients who had received no active medication
No DMARDs, biologics or corticosteroidsc 25,894 56.25 NA NA –
Sex
Male 15,230 33.09 15230 33.09 1
Female 30,800 66.91 30800 66.91 1
Note: ap value of 1 indicates cases with matched controls; bPharmacy data were used to compute an average daily dose during a 6-month period prior to cohort
entry. The average daily dose was unique for each individual course of corticosteroid therapy. ‘High dose’ referred to values that were greater than or equal to the
average daily dose, while ‘low dose’ referred to values that were less than the average daily dose; cFrom 1 year prior to cohort entry until the end of the study;
SD= standard deviation; IQR= interquartile range.
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in this age group with RA (Table 2).
Crude IRRs (Figure 2) and those adjusted for baseline
characteristics (Table 2 and Figure 2) showed signifi-
cantly increased rates of influenza or influenza complica-
tions in the overall population when RA was present,
although this effect was not observed in some patientsubgroups (see below). In the overall population (all
ages), the greatest increases in risk before baseline ad-
justment were noted for influenza complications (all
patients and those not taking DMARDs or biologics),
pneumonia complications, and stroke/MI complications
(Figure 2). The crude pneumonia complication risk was
more than doubled in patients with RA (Figure 2).
Table 2 Incidence rates (per 100,000 patient-years) of influenza and incidence rate ratios adjusted for baseline characteristics in patient subgroups
Incidence rates (per 100,000 patient-years) of influenza Incidence rate ratios adjusted for baseline characteristics (95% CI)
Parameter Age
categories
Males Females Total Males Females Total
RA cases Controls RA cases Controls RA cases Controls
Influenza 18–29 495.81 336.70 534.54 444.42 522.13 409.48 1.72 (0.50, 5.94) 1.54 (0.70, 3.38) 1.57 (0.81, 3.03)
30–39 761.26 347.99 633.31 387.97 670.90 375.64 2.07 (0.97, 4.38) 1.54 (0.93, 2.54) 1.65 (1.09, 2.51)
40–49 521.10 379.23 515.93 498.87 517.57 459.64 1.06 (0.62, 1.82) 0.88 (0.62, 1.24) 0.92 (0.69, 1.24)
50–59 358.50 245.10 381.06 357.66 373.58 319.45 1.38 (0.83, 2.32) 0.94 (0.68, 1.30) 1.06 (0.80, 1.38)
60–69 299.32 106.51 366.56 200.68 342.11 165.94 2.44 (1.13, 5.26) 1.75 (1.11, 2.76) 1.94 (1.31, 2.86)
≥70 309.20 238.81 314.97 252.78 312.93 247.95 0.97 (0.48, 1.96) 0.97 (0.58, 1.62) 0.98 (0.64, 1.48)
Overall 393.91 245.31 417.18 337.69 409.33 306.12 1.43 (1.09, 1.88) 1.13 (0.95, 1.35) 1.22 (1.05, 1.41)
Influenza complicationsa 18–29 70.05 0 0 0 22.45 0 – – –
30–39 57.49 0 71.98 0 67.71 0 – – –
40–49 38.61 32.78 71.96 31.89 61.36 32.18 0.45 (0.06, 3.44) 1.45 (0.43, 4.93) 1.10 (0.39, 3.07)
50–59 59.28 19.50 55.02 20.01 56.43 19.84 1.39 (0.26, 7.46) 2.06 (0.65, 6.47) 1.83 (0.71, 4.69)
60–69 59.53 35.44 63.02 13.79 61.76 21.77 1.08 (0.25, 4.70) 3.17 (0.67, 14.97) 2.15 (0.77, 6.0)
≥70 180.81 79.38 122.12 50.39 142.86 60.42 1.18 (0.39, 3.63) 1.76 (0.65, 4.74) 1.50 (0.71, 3.14)
Overall 80.28 34.08 71.95 23.55 74.76 27.15 1.30 (0.64, 2.63) 2.17 (1.22, 3.86) 1.82 (1.16, 2.81)
Influenza – no DMARDs
or biologics
18–29 541.94 343.41 609.33 456.87 587.11 419.88 1.72 (0.50, 5.49)) 1.54 (0.71, 3.38) 1.57 (0.81, 3.04)
30–39 804.93 352.17 670.75 377.68 710.76 369.80 2.07 (0.97, 4.38) 1.61 (0.97, 2.68) 1.71 (1.12, 2.61)
40–49 516.81 383.82 526.27 490.36 523.19 455.34 1.08 (0.63, 1.85) 0.90 (0.63, 1.28) 0.94 (0.70, 1.27)
50–59 387.17 247.13 399.08 358.47 395.08 320.48 1.38 (0.82, 2.31) 0.95 (0.69, 1.32) 1.06 (0.81, 1.40)
60–69 354.97 107.65 413.55 203.48 391.99 168.05 2.42 (1.12, 5.25) 1.81 (1.14, 2.86) 1.97 (1.33, 2.91)
≥70 304.73 240.80 270.23 238.58 282.70 239.35 0.93 (0.45, 1.92) 0.99 (0.57, 1.70) 0.96 (0.62, 1.49)
Overall 426.42 247.82 437.87 333.77 433.96 304.30 1.44 (1.09, 1.89) 1.17 (0.98, 1.40) 1.25 (1.07, 1.45)
Influenza complications –
no DMARDs or biologicsa
18–29 76.49 0 0 0 25.21 0 0 – –
30–39 60.73 0 77.64 0 72.59 0 0 – –
40–49 41.40 33.17 79.96 32.39 67.40 32.64 0.46 (0.06, 3.44) 1.45 (0.43, 4.93) 1.10 (0.39, 3.07)
50–59 65.34 19.66 57.68 20.35 60.25 20.11 1.39 (0.26, 7.46) 1.98 (0.62, 6.27) 1.77 (0.69, 4.56)
60–69 68.26 35.82 72.71 13.98 71.07 22.04 1.02 (0.23, 4.55) 3.56 (0.76, 16.66) 2.13 (0.76, 6.01)
≥70 145.29 80.04 112.16 42.47 124.13 55.49 0.99 (0.30, 3.28) 1.83 (0.62, 5.35) 1.40 (0.63, 3.08)
Overall 76.64 34.43 74.20 22.41 75.03 26.53 1.23 (0.59, 2.51) 2.23 (1.23, 4.03) 1.76 (1.12, 2.77)
Pneumonia complicationsb <65 49.38 31.92 90.34 34.93 76.75 33.91 1.00 (0.40, 2.45) 2.20 (1.26, 3.85) 1.78 (1.11, 2.85)
≥65 134.89 29.83 141.59 47.02 139.25 41.10 1.66 (0.44, 6.26) 2.12 (0.96, 4.68) 2.01 (1.02, 3.95)




















Table 2 Incidence rates (per 100,000 patient-years) of influenza and incidence rate ratios adjusted for baseline characteristics in patient subgroups (Continued)
Stroke/MI complicationsc <65 52.46 11.97 32.09 18.48 38.83 16.27 3.03 (0.85, 10.83) 1.27 (0.56, 2.90) 1.72 (0.87, 3.40)
≥65 87.68 19.90 101.67 47.03 96.78 37.68 2.11 (0.42, 10.50) 1.55 (0.68, 3.50) 1.68 (0.82, 3.47)
Overall 63.52 14.24 52.70 26.53 56.34 22.34 2.69 (1.0, 7.28) 1.37 (0.77, 2.44) 1.69 (1.02, 2.75)
Note: aInfluenza complications = pneumonia diagnosis (ICD-9 codes 480.xx–486.xx); stroke or MI (ICD-9 codes 410.xx, 430, 431, 432.x, 433.xx, 434.xx, 435.xx, 436); or neurological disorder (ICD-9 codes 320.xx–359.xx); all































































Figure 1 Incidence of influenza and complications in RA patients and controls recruited from the MarketScan database.
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patients (combined genders) aged 60–69 years, with most
of this risk increase being accounted for by men (Table 2).
There was also a noteworthy increase in risk in men aged
30–39 years. Similar results were observed in patients with
no history of use of DMARDs or biological therapies




Influenza complications – no 
DMARDs/biologics (adjusted)






Influenza – no DMARDs/biologics 
(crude)
Influenza complications – no 
DMARDs/biologics (crude)
0
Figure 2 Forest plot showing IRRs for influenza and complications in
(RA patients versus controls) are shown for each endpoint as overall figure
accounted for.Note that in some age groups (18–29 and 30–39 years),
IRRs for influenza complications could not be calculated.
This was because the control groups in these strata had
no record of influenza complications. Most other age
groups showed an increase in risk of complications in
patients with RA without attaining statistical significance
after adjustment for baseline factors, although significance1 2 3 4 5
IRR
patients drawn from the MarketScan database. IRRs
s for patients of all ages. Adjusted IRRs are those with baseline factors
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not in men alone) when data for all ages were combined
(Table 2). Men aged 40–49 years with RA showed a non-
significant reduction in risk of influenza complications
(IRR=0.45; 95% CI: 0.06, 3.44).
In men with RA with no history of DMARD or biological
use, there was an approximate halving of the risk of influ-
enza complications in men aged 40–49 years (IRR=0.46;
95% CI: 0.06, 3.44), and an increase in men aged 50–59
years (IRR=1.39; 95% CI: 0.26, 7.46; Table 2). In general,
however, the risk of influenza complications was similar in
RA patients not receiving DMARDs or biologics to that
seen in all RA patients (Table 2).
Adjusted IRRs (Table 2) showed an increased rate of
pneumonia among women with RA, with the greatest risk
observed among women aged <65 years. Stroke/MI compli-
cations were increased to a greater extent in men both be-
fore and after baseline adjustment, although statistical
significance was borderline after adjustment (Table 2 and
Figure 2).
Discussion
In this sample of patients from the MarketScan database,
the incidence of influenza was higher in those with RA than
in matched controls. After adjustment for baseline factors,
the risk of influenza was significantly increased in patients
with RA, with both genders aged 60–69 years and men
aged 30–39 years being particularly at risk. Of note is the
observation that the incidence of influenza was increased
similarly in patients not taking DMARDs or biological ther-
apies and in the overall RA population.
Risks of complications could not be calculated or were
not significant in some individual age groups and genders,
although pooled data from all ages generally showed
increased IRRs after adjustment for baseline factors, regard-
less of whether or not DMARDs or biologics were being
taken. When individual age groups were analysed, women
with RA appeared to be at greater risk of influenza compli-
cations than men. Analysis of individual age groups showed
the risk of pneumonia to be increased significantly in
women aged <65 years (in contrast to the results before
baseline corrections were applied); stroke/MI risk was
increased to a greater extent in men with RA.
Infections noted as complications of RA have been
reported frequently over the past few decades. In particular,
septic arthritis and pulmonary infections have been
described since the 1960s/70s [18,19]. Studies in smaller
cohorts of patients have shown results similar to those in
the present study for rates of infection generally. Doran
et al. [1] found that patients with RA have nearly twice the
rate of infection seen in controls (although these authors
excluded patients with upper respiratory tract infections).
This study included 609 patients with RA and 609 matched
controls, with median age 58 years, and showedhazard ratios of 1.70, 1.83 and 1.45 for objectively con-
firmed infections, infections requiring hospitalisation and
any documented infection, respectively, in patients with
RA. The respiratory tract was identified as an infection site
of high risk.
Potential explanations for increased risk of infection gen-
erally in patients with RA include immunological abnor-
malities involving circulating T cells, which may impair the
ability of the immune system to respond to infection. One
study has shown a marked reduction in the ability of
patients with RA to produce T cells and to maintain T cell
homeostasis [20]. Impaired thymic function may also be
involved, with increased T cell turnover in the periphery
being a secondary mechanism [20]. Other factors may in-
clude those related to RA itself (poor mobility or effects of
joint surgery) or its extra-articular manifestations. Doran
et al. [1] also cited comorbidities such as diabetes as poten-
tial contributing factors to increased risk of infection in RA,
but in the present study risk of influenza specifically per-
sisted after commonly observed chronic comorbidities were
accounted for by IRR adjustment.
The use of DMARDs and biologics is reported to increase
risk of infection generally in RA patients [21,22]. Corticos-
teroids have many immunosuppressive effects that induce
cellular immunodeficiency, necessitating careful timing of
administration to accompany diurnal cortisol secretion pat-
terns and the use of the lowest possible dosages [21]. More-
over, tumour necrosis factor (TNF)-α plays a key role in the
pathogenesis of RA, and the propensity of anti-TNF-α
agents to facilitate infection in patients with RA is a source
of concern. This is reflected in the recent labelling update
issued by the Food and Drug Administration [23], in which
the warnings and precautions for TNF-α inhibitors have
been revised to ensure consistency of information on the
risk of serious infections and the associated pathogens.
Most notably, the ‘Boxed Warning’ for these agents now
includes the risk of infection from Legionella and Listeria.
Patients and physicians are urged to be vigilant for signs of
infection when using these drugs [21].
Despite the above concerns, Furst [22] has reported that
influenza vaccination is effective in the presence of TNF
inhibitors or abatacept. We found similar increases in risk
whether DMARDs/biologics were used or not after control-
ling for baseline factors including vaccination. We note
however, that the present study, unlike those cited above,
focused exclusively on influenza in patients with RA ra-
ther than on infectious disease in general. Most recently,
data obtained in 340 patients with RA and 234 control
patients at a Brazilian hospital have shown seroprotection
rates after immunisation to be more than 20% lower for
RA patients than for patients who did not have the dis-
ease (60.1% vs 82.9%; p <0.001) [24]. Seroconversion rates
were similarly reduced (antibodies in 53.4% of RA
patients and 76.9% of controls; p < 0.001).
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state that persons with RA have an increased risk of re-
spiratory infections such as influenza, together with a raised
risk of complications and hospitalisation [25]. In their guid-
ance for the 2010–2011 season, the CDC recommended
annual vaccination for all persons aged 6 months or over,
with protection of persons at higher risk for influenza com-
plications continuing to be a focus for vaccination efforts
[26]. Although not specifically mentioned in these guide-
lines, patients with inflammatory forms of arthritis (includ-
ing RA) are now listed as an at-risk group in a September
2010 update on arthritis and influenza [25].
The increased risk of pneumonia in this study is in ac-
cordance with UK data based on a large primary care data-
base that showed an adjusted OR for pneumonia of 1.84 in
patients of all ages with RA (n=387) relative to controls
(n=821) [9]. These researchers found, as in the present
study, that adjustment for potentially confounding baseline
variables tended to reduce risk.
Although we showed increased risk of influenza in
patients with RA regardless of whether DMARDs or
biologics were used or not, our study was limited by
its inability to show the effect, if any, of the use of
these agents on the severity of influenza infection.
Such an effect requires further investigation in light of
the continuing progress being made with drugs that
target the immunological mechanisms underlying RA.
In addition, it is not clear whether the results of this
study sample are generalisable to the overall US popu-
lation. Inclusion/exclusion criteria were not especially
strict. Patients not continuously enrolled for 1 year be-
fore or after cohort entry, and those with a diagnosis
of RA or evidence of an RA-related disease in the year
preceding the cohort entry, were excluded. While RA
patients are likely to be immunocompromised, it is un-
likely that a health professional would closely monitor
an RA patient specifically for influenza or influenza
complications compared with anyone else in the gen-
eral population. Thus, any selection bias may be non-
differential and minimal. In addition, the statistical
models accounted for baseline differences in the RA
and matched comparison cohorts. Similarly, any mis-
classification of an influenza-associated complication
would be no more likely to occur in an RA cohort
than in the comparison group. Nevertheless, this study
may be among the few to examine the association be-
tween RA and influenza or its complications in such a
large patient population with or without prescription
of DMARDs or biologics.
Conclusions
RA is known to be a risk factor for increased incidence
and risk of complications of infectious diseases. Previ-
ously published data have shown this increase in risk toinclude upper respiratory disease, notably pneumonia.
Analysis of gender- and age-specific subgroups showed
in particular that women were at greater risk than men
for complications generally, but that risk of stroke and
MI complications was increased mainly in men. The
data presented here show that RA is associated with
increased risk of seasonal influenza and its complica-
tions specifically, concordant with the position now
being taken by the CDC on influenza risk in patients
with inflammatory rheumatic disease; the prescription of
DMARDs or biologics appeared not to affect the inci-
dence of influenza or its complications in RA patients.
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